Allogene Therapeutics Quarterly Balance Sheets Chart
Quarterly
|
Annual
Allogene Therapeutics Quarterly Balance Sheets Table
Quarterly
|
Annual
| Unit: USD | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 | 2021-09-30 | 2021-06-30 | 2021-03-31 | 2020-12-31 | 2020-09-30 | 2020-06-30 | 2020-03-31 | 2019-12-31 | 2019-09-30 | 2019-06-30 | 2019-03-31 | 2018-12-31 | 2018-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| assets | ||||||||||||||||||||||||||||
| current assets: | ||||||||||||||||||||||||||||
| cash and cash equivalents | 52,332,000 | 42,455,000 | 75,218,000 | 51,239,000 | 170,667,000 | 51,039,000 | 83,155,000 | 69,246,000 | 154,758,000 | 109,931,000 | 61,904,000 | 74,357,000 | 96,041,000 | 84,514,000 | 173,314,000 | 190,021,000 | 223,503,000 | 236,865,000 | 183,351,000 | 158,136,000 | 280,379,000 | 135,897,000 | 175,126,000 | 160,990,000 | 112,584,000 | 92,748,000 | 92,432,000 | 83,141,000 |
| short-term investments | 220,788,000 | 237,588,000 | 217,258,000 | 240,325,000 | 273,961,000 | 333,821,000 | 365,542,000 | 396,259,000 | 337,204,000 | 361,293,000 | 455,416,000 | 477,872,000 | 394,451,000 | 364,536,000 | 283,988,000 | 293,464,000 | 364,204,000 | 462,716,000 | 644,559,000 | 682,886,000 | 619,271,000 | 357,026,000 | 355,407,000 | 340,254,000 | 389,840,000 | 373,392,000 | 366,952,000 | 161,080,000 |
| prepaid expenses and other current assets | 9,535,000 | 11,533,000 | 10,910,000 | 12,851,000 | 12,496,000 | 10,504,000 | 10,418,000 | 7,949,000 | 10,139,000 | 10,241,000 | 11,504,000 | 16,832,000 | 22,536,000 | 20,694,000 | 14,021,000 | 19,373,000 | 14,464,000 | 16,480,000 | 17,220,000 | 13,036,000 | 9,927,000 | 11,491,000 | 14,043,000 | 8,513,000 | 9,118,000 | 10,487,000 | 8,598,000 | 3,132,000 |
| total current assets | 282,655,000 | 291,576,000 | 303,386,000 | 304,415,000 | 457,124,000 | 395,364,000 | 459,115,000 | 473,454,000 | 502,101,000 | 481,465,000 | 528,824,000 | 569,061,000 | 513,028,000 | 469,744,000 | 471,323,000 | 502,858,000 | 602,171,000 | 716,061,000 | 845,130,000 | 854,058,000 | 909,577,000 | 504,414,000 | 544,576,000 | 509,757,000 | 511,542,000 | 476,627,000 | 467,982,000 | 247,353,000 |
| long-term investments | 29,510,000 | 55,506,000 | 80,673,000 | 111,821,000 | 12,405,000 | 32,170,000 | 52,586,000 | 42,788,000 | 59,151,000 | 85,108,000 | 195,637,000 | 284,093,000 | 352,179,000 | 378,222,000 | 325,523,000 | 264,573,000 | 204,208,000 | 207,993,000 | 210,794,000 | 60,121,000 | 58,322,000 | 100,702,000 | 147,769,000 | 214,588,000 | 261,966,000 | 154,045,000 | ||
| operating lease right-of-use asset | 41,966,000 | 44,075,000 | 45,205,000 | 46,313,000 | 58,385,000 | 64,483,000 | 63,703,000 | 78,643,000 | 80,314,000 | 81,964,000 | 83,592,000 | 85,245,000 | 86,837,000 | 57,057,000 | 58,030,000 | 38,764,000 | 39,474,000 | 40,189,000 | 41,295,000 | 41,557,000 | 42,432,000 | 43,836,000 | 44,495,000 | 31,437,000 | 31,880,000 | 32,394,000 | 33,015,000 | 24,996,000 |
| property and equipment | 78,858,000 | 82,992,000 | 86,056,000 | 88,989,000 | 92,080,000 | 95,931,000 | 99,478,000 | 102,826,000 | 106,386,000 | 109,849,000 | 112,839,000 | 114,442,000 | 117,216,000 | 120,200,000 | 122,990,000 | 125,883,000 | 125,459,000 | 123,146,000 | 118,840,000 | 102,653,000 | 84,605,000 | 66,349,000 | 56,449,000 | 45,943,000 | 35,817,000 | 20,426,000 | 8,595,000 | 4,693,000 |
| deposit placed in escrow | 23,484,000 | 21,641,000 | 20,773,000 | 22,320,000 | 21,429,000 | |||||||||||||||||||||||
| restricted cash | 10,292,000 | 10,292,000 | 10,292,000 | 10,292,000 | 10,292,000 | 10,292,000 | 10,292,000 | 10,292,000 | 10,292,000 | 10,292,000 | 10,292,000 | 10,292,000 | 10,292,000 | 10,292,000 | 10,292,000 | 9,449,000 | 9,449,000 | 9,449,000 | 9,449,000 | 9,449,000 | 4,299,000 | 4,299,000 | 4,299,000 | 4,299,000 | 4,299,000 | 4,299,000 | 1,299,000 | 937,000 |
| other long-term assets | 3,828,000 | 1,900,000 | 2,325,000 | 4,970,000 | 6,439,000 | 5,159,000 | 6,604,000 | 9,576,000 | 9,382,000 | 9,389,000 | 9,564,000 | 9,378,000 | 8,938,000 | 9,042,000 | 5,815,000 | 6,160,000 | 5,829,000 | 6,275,000 | 5,169,000 | 2,274,000 | 2,160,000 | 4,675,000 | 4,618,000 | 3,105,000 | 2,238,000 | 432,000 | 244,000 | 2,307,000 |
| total assets | 470,593,000 | 507,982,000 | 548,710,000 | 589,120,000 | 646,883,000 | 586,350,000 | 642,837,000 | 712,326,000 | 770,971,000 | 746,871,000 | 817,079,000 | 887,572,000 | 947,644,000 | 964,632,000 | 1,038,634,000 | 1,079,246,000 | 1,126,724,000 | 1,179,044,000 | 1,227,829,000 | 1,222,500,000 | 1,258,544,000 | 688,523,000 | 717,802,000 | 695,544,000 | 733,997,000 | 749,369,000 | 773,855,000 | 435,235,000 |
| liabilities and stockholders’ equity | ||||||||||||||||||||||||||||
| current liabilities: | ||||||||||||||||||||||||||||
| accounts payable | 4,851,000 | 5,058,000 | 5,394,000 | 5,506,000 | 12,936,000 | 5,779,000 | 5,897,000 | 6,205,000 | 10,229,000 | 14,688,000 | 13,890,000 | 11,045,000 | 9,713,000 | 8,708,000 | 10,255,000 | 11,499,000 | 11,005,000 | 14,875,000 | 10,390,000 | 10,151,000 | 9,057,000 | 7,199,000 | 9,250,000 | 8,047,000 | 23,503,000 | 12,976,000 | 12,338,000 | 3,083,000 |
| accrued and other current liabilities | 26,824,000 | 24,964,000 | 30,129,000 | 27,065,000 | 24,369,000 | 25,029,000 | 31,096,000 | 31,195,000 | 44,263,000 | 44,624,000 | 39,743,000 | 36,938,000 | 34,360,000 | 27,763,000 | 37,496,000 | 41,626,000 | 34,688,000 | 39,735,000 | 44,938,000 | 39,979,000 | 31,838,000 | 19,619,000 | 23,829,000 | 25,307,000 | 14,497,000 | 14,289,000 | 17,121,000 | 16,779,000 |
| total current liabilities | 31,675,000 | 30,022,000 | 35,523,000 | 32,571,000 | 37,305,000 | 30,894,000 | 37,079,000 | 37,636,000 | 54,721,000 | 59,585,000 | 54,518,000 | 48,872,000 | 44,909,000 | 36,877,000 | 48,174,000 | 53,490,000 | 45,998,000 | 54,849,000 | 94,320,000 | 50,130,000 | 40,895,000 | 26,818,000 | 33,079,000 | 33,354,000 | 38,000,000 | 27,265,000 | 29,459,000 | 159,477,000 |
| lease liability, noncurrent | 79,241,000 | 81,292,000 | 83,247,000 | 86,989,000 | 88,916,000 | 88,346,000 | 95,122,000 | 69,929,000 | 50,809,000 | 50,846,000 | 51,067,000 | 51,536,000 | 51,349,000 | 37,689,000 | 34,867,000 | 34,811,000 | 34,456,000 | 25,661,000 | ||||||||||
| other long-term liabilities | 15,116,000 | 11,275,000 | 7,761,000 | 7,666,000 | 7,551,000 | 5,173,000 | 5,179,000 | 1,486,000 | 1,523,000 | 1,510,000 | 1,569,000 | 2,033,000 | 2,554,000 | 3,490,000 | 4,125,000 | 5,175,000 | 5,705,000 | 2,791,000 | 3,083,000 | 2,793,000 | 3,163,000 | 3,650,000 | 4,351,000 | 4,785,000 | 5,495,000 | 6,065,000 | 6,776,000 | 7,488,000 |
| total liabilities | 126,032,000 | 122,589,000 | 126,531,000 | 125,372,000 | 131,845,000 | 124,983,000 | 130,604,000 | 129,224,000 | 148,065,000 | 154,609,000 | 151,209,000 | 147,611,000 | 145,695,000 | 109,402,000 | 122,228,000 | 109,304,000 | 102,912,000 | 109,265,000 | 148,212,000 | 103,769,000 | 95,125,000 | 82,004,000 | 88,779,000 | 75,828,000 | 78,362,000 | 68,141,000 | 70,691,000 | 192,626,000 |
| commitments and contingencies | ||||||||||||||||||||||||||||
| stockholders’ equity: | ||||||||||||||||||||||||||||
| preferred stock, 0.001 par value: 10,000,000 shares authorized as of june 30, 2025 and december 31, 2024; no shares were issued and outstanding as of june 30, 2025 and december 31, 2024 | ||||||||||||||||||||||||||||
| common stock | 220,000 | 219,000 | 212,000 | 210,000 | 209,000 | 170,000 | 169,000 | 168,000 | 167,000 | 146,000 | 144,000 | 144,000 | 144,000 | 143,000 | 142,000 | 142,000 | 142,000 | 141,000 | 140,000 | 140,000 | 139,000 | 125,000 | 124,000 | 122,000 | 122,000 | 121,000 | 121,000 | 31,000 |
| additional paid-in capital | 2,274,885,000 | 2,264,687,000 | 2,241,879,000 | 2,223,265,000 | 2,209,200,000 | 2,089,357,000 | 2,075,252,000 | 2,059,333,000 | 2,039,263,000 | 1,932,734,000 | 1,911,632,000 | 1,893,908,000 | 1,871,262,000 | 1,847,534,000 | 1,822,179,000 | 1,798,678,000 | 1,774,298,000 | 1,749,097,000 | 1,725,552,000 | 1,695,411,000 | 1,673,026,000 | 1,055,386,000 | 1,023,876,000 | 952,820,000 | 937,709,000 | 922,816,000 | 914,265,000 | 12,693,000 |
| accumulated deficit | -1,930,499,000 | -1,879,556,000 | -1,819,823,000 | -1,759,884,000 | -1,693,591,000 | -1,627,233,000 | -1,562,233,000 | -1,473,988,000 | -1,412,673,000 | -1,334,684,000 | -1,235,980,000 | -1,141,133,000 | -1,057,985,000 | -983,198,000 | -903,348,000 | -828,480,000 | -750,294,000 | -679,358,000 | -646,343,000 | -577,773,000 | -511,576,000 | -450,602,000 | -396,122,000 | -335,092,000 | -284,357,000 | -243,114,000 | -211,528,000 | -181,019,000 |
| accumulated other comprehensive loss | -45,000 | -89,000 | -780,000 | -927,000 | -955,000 | -2,411,000 | -3,851,000 | -5,934,000 | -9,926,000 | -12,958,000 | -11,472,000 | -148,000 | ||||||||||||||||
| total stockholders’ equity | 344,561,000 | 385,393,000 | 422,179,000 | 463,748,000 | 515,038,000 | 461,367,000 | 512,233,000 | 583,102,000 | 622,906,000 | 592,262,000 | 665,870,000 | 739,961,000 | 801,949,000 | 855,230,000 | 916,406,000 | 969,942,000 | 1,023,812,000 | 1,069,779,000 | 1,079,617,000 | 1,118,731,000 | 1,163,419,000 | 606,519,000 | 629,023,000 | 619,716,000 | 655,635,000 | 681,228,000 | 703,164,000 | |
| total liabilities and stockholders’ equity | 470,593,000 | 507,982,000 | 548,710,000 | 589,120,000 | 646,883,000 | 586,350,000 | 642,837,000 | 712,326,000 | 770,971,000 | 746,871,000 | 817,079,000 | 887,572,000 | 947,644,000 | 964,632,000 | 1,038,634,000 | 1,079,246,000 | 1,126,724,000 | 1,179,044,000 | 1,227,829,000 | 1,222,500,000 | 1,258,544,000 | 688,523,000 | 717,802,000 | 695,544,000 | 733,997,000 | 749,369,000 | ||
| preferred stock, 0.001 par value: 10,000,000 shares authorized as of march 31, 2025 and december 31, 2024; no shares were issued and outstanding as of march 31, 2025 and december 31, 2024 | ||||||||||||||||||||||||||||
| accumulated other comprehensive income | 43,000 | -2,567,000 | -398,000 | -334,000 | -101,000 | 268,000 | 953,000 | 1,830,000 | 1,610,000 | 1,145,000 | 1,866,000 | 2,161,000 | 1,405,000 | 306,000 | ||||||||||||||
| equity method investments | 1,134,000 | 2,716,000 | 3,645,000 | |||||||||||||||||||||||||
| preferred stock, 0.001 par value: 10,000,000 authorized as of december 31, 2024 and december 31, 2023; no shares were issued and outstanding as of december 31, 2024 and december 31, 2023 | ||||||||||||||||||||||||||||
| operating lease liability, noncurrent | 85,135,000 | |||||||||||||||||||||||||||
| preferred stock, 0.001 par value: 10,000,000 shares authorized as of september 30, 2024 and december 31, 2023; no shares were issued and outstanding as of september 30, 2024 and december 31, 2023 | ||||||||||||||||||||||||||||
| accumulated other comprehensive income/ | 157,000 | |||||||||||||||||||||||||||
| preferred stock, 0.001 par value: 10,000,000 shares authorized as of june 30, 2024 and december 31, 2023; no shares were issued and outstanding as of june 30, 2024 and december 31, 2023 | ||||||||||||||||||||||||||||
| deferred revenue | 86,000 | 86,000 | 236,000 | 229,000 | 273,000 | 885,000 | 889,000 | 836,000 | 406,000 | 423,000 | 365,000 | 305,000 | 239,000 | 38,992,000 | ||||||||||||||
| preferred stock, 0.001 par value: 10,000,000 shares authorized as of march 31, 2024 and december 31, 2023; no shares were issued and outstanding as of march 31, 2024 and december 31, 2023 | ||||||||||||||||||||||||||||
| preferred stock, 0.001 par value: 10,000,000 authorized as of december 31, 2023 and december 31, 2022; no shares were issued and outstanding as of december 31, 2023 and december 31, 2022 | ||||||||||||||||||||||||||||
| equity method investment | 5,365,000 | 9,910,000 | 11,124,000 | 12,817,000 | 14,046,000 | 15,696,000 | 14,204,000 | 18,005,000 | 17,910,000 | 18,819,000 | 19,351,000 | 3,738,000 | 4,516,000 | 4,677,000 | 4,829,000 | 4,892,000 | ||||||||||||
| lease liability, non-current | 90,102,000 | 91,821,000 | 93,514,000 | 96,706,000 | 98,232,000 | 69,035,000 | 50,639,000 | 51,209,000 | 51,625,000 | |||||||||||||||||||
| preferred stock, 0.001 par value: 10,000,000 shares authorized as of september 30, 2023 and december 31, 2022; no shares were issued and outstanding as of september 30, 2023 and december 31, 2022 | ||||||||||||||||||||||||||||
| preferred stock, 0.001 par value: 10,000,000 shares authorized as of june 30, 2023 and december 31, 2022; no shares were issued and outstanding as of june 30, 2023 and december 31, 2022 | ||||||||||||||||||||||||||||
| preferred stock, 0.001 par value: 10,000,000 shares authorized as of march 31, 2023 and december 31, 2022; no shares were issued and outstanding as of march 31, 2023 and december 31, 2022 | ||||||||||||||||||||||||||||
| preferred stock, 0.001 par value: 10,000,000 authorized as of december 31, 2022 and december 31, 2021; no shares were issued and outstanding as of december 31, 2022 and december 31, 2021 | ||||||||||||||||||||||||||||
| preferred stock, 0.001 par value: 10,000,000 shares authorized as of september 30, 2022 and december 31, 2021; no shares were issued and outstanding as of september 30, 2022 and december 31, 2021 | ||||||||||||||||||||||||||||
| preferred stock, 0.001 par value: 10,000,000 shares authorized as of june 30, 2022 and december 31, 2021; no shares were issued and outstanding as of june 30, 2022 and december 31, 2021 | ||||||||||||||||||||||||||||
| preferred stock, 0.001 par value: 10,000,000 shares authorized as of march 31, 2022 and december 31, 2021; no shares were issued and outstanding as of march 31, 2022 and december 31, 2021 | ||||||||||||||||||||||||||||
| accumulated other comprehensive | -9,249,000 | |||||||||||||||||||||||||||
| preferred stock, 0.001 par value: 10,000,000 authorized as of december 31, 2021 and december 31, 2020; no shares were issued and outstanding as of december 31, 2021 and december 31, 2020 | ||||||||||||||||||||||||||||
| preferred stock, 0.001 par value: 10,000,000 shares authorized as of september 30, 2021 and december 31, 2020; no shares were issued and outstanding as of september 30, 2021 and december 31, 2020 | ||||||||||||||||||||||||||||
| preferred stock, 0.001 par value: 10,000,000 shares authorized as of june 30, 2021 and december 31, 2020; no shares were issued and outstanding as of june 30, 2021 and december 31, 2020 | ||||||||||||||||||||||||||||
| preferred stock, 0.001 par value: 10,000,000 shares authorized as of march 31, 2021 and december 31, 2020; no shares were issued and outstanding as of march 31, 2021 and december 31, 2020 | ||||||||||||||||||||||||||||
| intangible assets | 151,000 | 301,000 | 452,000 | 603,000 | 754,000 | 904,000 | ||||||||||||||||||||||
| liabilities, convertible preferred stock and stockholders’ equity | ||||||||||||||||||||||||||||
| preferred stock, 0.001 par value: 10,000,000 authorized as of december 31, 2020 and december 31, 2019; no shares were issued and outstanding as of december 31, 2020 and december 31, 2019 | ||||||||||||||||||||||||||||
| preferred stock, 0.001 par value: 10,000,000 shares authorized as of september 30, 2020 and december 31, 2019; no shares were issued and outstanding as of september 30, 2020 and december 31, 2019 | ||||||||||||||||||||||||||||
| preferred stock, 0.001 par value: 10,000,000 shares authorized as of june 30, 2020 and december 31, 2019; no shares were issued and outstanding as of june 30, 2020 and december 31, 2019 | ||||||||||||||||||||||||||||
| preferred stock, 0.001 par value: 10,000,000 shares authorized as of march 31, 2020 and december 31, 2019; no shares were issued and outstanding as of march 31, 2020 and december 31, 2019 | ||||||||||||||||||||||||||||
| preferred stock, 0.001 par value: 10,000,000 authorized as of december 31, 2019 and december 31, 2018, respectively; no shares were issued and outstanding as of december 31, 2019 and december 31, 2018 | ||||||||||||||||||||||||||||
| preferred stock, 0.001 par value: 10,000,000 shares authorized as of september 30, 2019 and december 31, 2018; no shares were issued and outstanding as of september 30, 2019 and december 31, 2018 | ||||||||||||||||||||||||||||
| preferred stock, 0.001 par value: 10,000,000 shares authorized as of june 30, 2019 and december 31, 2018; no shares were issued and outstanding as of june 30, 2019 and december 31, 2018 | ||||||||||||||||||||||||||||
| preferred stock, 0.001 par value: 10,000,000 shares authorized as of march 31, 2019 and december 31, 2018; no shares were issued and outstanding as of march 31, 2019 and december 31, 2018 | ||||||||||||||||||||||||||||
| convertible preferred stock, 0.001 par value; no shares and 1,000,000 shares authorized as of december 31, 2018 and december 31, 2017, respectively; no shares issued and outstanding as of december 31, 2018 and december 31, 2017 | ||||||||||||||||||||||||||||
| stockholders’ equity | ||||||||||||||||||||||||||||
| preferred stock, 0.001 par value: 10,000,000 and no shares authorized as of december 31, 2018 and december 31, 2017, respectively; no shares were issued and outstanding as of december 31, 2018 | ||||||||||||||||||||||||||||
| notes receivable from common stockholders | ||||||||||||||||||||||||||||
| total liabilities, convertible preferred stock and stockholders’ equity | 773,855,000 | |||||||||||||||||||||||||||
| liabilities, convertible preferred stock and stockholders’ deficit | ||||||||||||||||||||||||||||
| convertible notes payable | 139,615,000 | |||||||||||||||||||||||||||
| convertible preferred stock, 0.001 par value; 11,743,987 and 1,000,000 shares authorized as of september 30, 2018 and december 31, 2017, respectively; 11,743,987 shares and no shares issued and outstanding as of september 30, 2018 and december 31, 2017, respectively; aggregate liquidation preference of 411.8 million as of september 30, 2018 | 411,052,000 | |||||||||||||||||||||||||||
| stockholders’ deficit: | ||||||||||||||||||||||||||||
| total stockholders’ deficit | -168,443,000 | |||||||||||||||||||||||||||
| total liabilities, convertible preferred stock and stockholders’ deficit | 435,235,000 |
We provide you with 20 years of balance sheets for Allogene Therapeutics stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as asset and liabilities, payables and receivables, long debts and short debts, cash and inventories, expenses and profits. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Allogene Therapeutics. Explore the full financial landscape of Allogene Therapeutics stock with our expertly curated balance sheets.
The information provided in this report about Allogene Therapeutics stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.